Disease-modifying anti-rheumatic drugs til behandling af ankyloserende spondylitis

TY - JOUR

T1 - Disease-modifying anti-rheumatic drugs til behandling af ankyloserende spondylitis

AU - Madsen, Ole Rintek

AU - Egsmose, Charlotte

N1 - Keywords: Antibodies, Monoclonal; Antirheumatic Agents; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Methotrexate; Spondylitis, Ankylosing; Sulfasalazine; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton, peripheral joints, entheses and extra-articular sites. Patients with early disease, a higher level of erythrocyte sedimentation rate and/or peripheral arthritis might benefit from sulfasalazine. Otherwise, there is no evidence that disease-modifying anti-rheumatic (DMARDs) have a therapeutic effect in AS. Clinical evidence that greater TNF-inhibitor effectiveness can be achieved by combining with a DMARD is lacking, but further studies should be performed. More research is needed to clarify the role of DMARDs in the treatment of AS. Udgivelsesdato: 2009-Aug

AB - Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton, peripheral joints, entheses and extra-articular sites. Patients with early disease, a higher level of erythrocyte sedimentation rate and/or peripheral arthritis might benefit from sulfasalazine. Otherwise, there is no evidence that disease-modifying anti-rheumatic (DMARDs) have a therapeutic effect in AS. Clinical evidence that greater TNF-inhibitor effectiveness can be achieved by combining with a DMARD is lacking, but further studies should be performed. More research is needed to clarify the role of DMARDs in the treatment of AS. Udgivelsesdato: 2009-Aug

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 171

SP - 2268

EP - 2272

JO - Ugeskrift for læger

JF - Ugeskrift for læger

IS - 33

ER -